The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 17: 2248 - 2252

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.17.017

Drugs and Clinic Practice

Efficacy and safety of Anlotinib combined with PD⁃1 blockades for extensive⁃stage small⁃cell lung cancer

  • Jianguo LI ,
  • Shuman LI ,
  • Hui. CHEN
Expand
  • *.Surgery Department，Tianjin Beichen Hospital，Tianjin 300400，China

Received date: 2023-05-29

  Online published: 2023-09-27

Fold

Abstract

Objective To investigate the efficacy and safety of Anlotinib combined with PD-1 blockades in patients with extensive-stage small-cell lung cancer （ES-SCLC）. Methods This study retrospectively analyzed the data of 36 patients with ES-SCLC who were treated with at least one previous systematic chemotherapy regimen. All the patients received Anlotinib plus PD-1 blockades therapy. Results Efficacy evaluation and safety analysis were conducted in all the patients. The best efficacy results showed objective response rate was 27.8% （95%CI：14.2% ~ 45.2%）； disease control rate 80.6% （95%CI： 64.0% ~ 91.8%）. The PFS and OS of the 36 patients were 4.6 months （95%CI： 3.1 ~ 6.1） and 9.3 months （95%CI： 3.3 ~ 15.3）， respectively， indicating that overall adverse reactions were tolerate and controllable. Multivariate cox regression analysis for PFS indicated that ECOG performance status was the independent factor to predict PFS. Conclusion Anlotinib combined with PD-1 blockades regimen preliminarily demonstrates encouraging efficacy and tolerable safety for patients with ES-SCLC in real-world clinical practice.

Key words： small-cell lung cancer; anlotinib; PD-1 blockade; efficacy; safety

Cite this article

Jianguo LI , Shuman LI , Hui. CHEN . Efficacy and safety of Anlotinib combined with PD⁃1 blockades for extensive⁃stage small⁃cell lung cancer[J]. The Journal of Practical Medicine, 2023 , 39(17) : 2248 -2252 . DOI: 10.3969/j.issn.1006-5725.2023.17.017

References

1 CALLES A， AGUADO G， SANDOVAL C， et al. The role of immunotherapy in small cell lung cancer［J］. Clin Transl Oncol， 2019， 21（8）： 961-976.
2 GUO H G， WEI J， LI X， et al. Do socioeconomic factors modify the effects of PM1 and SO2 on lung cancer incidence in China？［J］. Sci Total Environ， 2021， 756： 143998.
3 WANG Y W， ZOU S Y， ZHAO Z Y， et al. New insights into small-cell lung cancer development and therapy［J］. Cell Biol Int， 2020， 44（8）： 1564-1576.
4 熊艳， 陈海文， 牛玉春， 等. 肺内和肺外小细胞癌基本临床特征的比较［J］. 实用医学杂志， 2023， 39（05）： 564-571.
5 MONTANINO A， MANZO A， CARILLIO G， et al. Angiogenesis Inhibitors in Small Cell Lung Cancer［J］. Front Oncol. 2021， 11： 655316.
6 CHENG Y， WANG Q M， LI K， et al. Anlotinib vs placebo as third-or further-line treatment for patients with small cell lung cancer： a randomised， double-blind， placebo-controlled Phase 2 study［J］. Br J Cancer， 2021， 125（3）： 366-371.
7 OGINO A， CHOI J， LIN M， et al. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations［J］. Mol Oncol， 2021， 15（1）： 27-42.
8 HORN L， MANSFIELD A S， SZCZESNA A， et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer［J］. N Engl J Med， 2018， 379（23）： 2220-2229.
9 PA L， DVORKIN M， CHEN Y B， et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer （CASPIAN）： a randomised， controlled， open-label， phase 3 trial［J］. Lancet， 2019， 394（10212）： 1929-1939.
10 LIM J U， KANG H S. A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer［J］. Ann Transl Med， 2021， 9（9）：809.
11 SONG Y， FU Y， XIE Q， et al. Anti-angiogenic agents in combination with immune checkpoint inhibitors： a promising strategy for cancer treatment ［J］. Front Immunol， 2020， 11： 1956.
12 FINN R S， QIN S， IKEDA M， et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］. N Engl J Med， 2020， 382（20）： 1894-1905.
13 CHENG Y， WANG Q M， LI K， et al. OA13.03 anlotinib as third-line or further-line treatment in relapsed SCLC： a multicentre， randomized， double-blind phase 2 trial［J］. J Thorac Oncol， 2018， 13（10）： S351-S352.
14 MILLER T P， FISHER B T， GETZ K D， et al. Unintended consequences of evolution of the common terminology criteria for adverse events［J］. Pediatr Blood Cancer， 2019， 66（7）： e27747.
15 ANTONIA S J， LOPEZ-MARTIN J A， BENDELL J， et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer （CheckMate 032）： a multicentre， open-label， phase 1/2 trial［J］. Lancet Oncol， 2016， 17（7）： 883-895.
16 CHUNG H C， PIHA-PAUL S A， LOPEZ-MARTIN J， et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC： results from the KEYNOTE-028 and KEYNOTE-158 studies［J］. J Thorac Oncol， 2020， 15（4）： 618-627.
17 OTT P A， ELEZ E， HIRET S， et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer： results from the phase Ib KEYNOTE-028 study［J］. J Clin Oncol， 2017， 35（34）： 3823-3829.
18 HURWITZ J L， MCCOY F， SCULLIN P， et al. New advances in the second-line treatment of small cell lung cancer ［J］. Oncologist， 2009， 14（10）： 986-994.
19 TRIGO J， SUBBIAH V， BESSE B， et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer： a single-arm， open-label， phase 2 basket trial［J］. Lancet Oncol， 2020， 21（5）： 645-654.
20 SPIGEL D R， VICENTE D， CIULEANU T E， et al. Second-line nivolumab in relapsed small-cell lung cancer： Check Mate 331 ［J］. Ann Oncol， 2021， 32（5）： 631-641.
21 FAN Y， ZHAO J， WANG Q M， et al. Camrelizumab plus apatinib in extensive-stage SCLC （PASSION）： a multicenter， two-stage， phase 2 trial［J］. J Thorac Oncol， 2021， 16（2）： 299-309.
22 ASAO T， WATANABE S， TANAKA T， et al. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer （ES-SCLC） patients with a poor performance status （PS）： NEJ045A study protocol ［J］. BMC Cancer， 2022， 22（1）： 1135.
23 RADES D， MOTISI L， VENINGA T， et al. Predictors of outcomes and a scoring system for estimating survival in patients treated with radiotherapy for metastatic spinal cord compression from small-cell lung cancer［J］. Clin Lung Cancer， 2019， 20（4）： 322-329.
24 ZHANG C G， YANG S， CHEN J H， et al. Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy ［J］. J Clin Oncol， 2021 39（）： 8568-8568.
25 MA S X， HE Z， WANG L L， et al. Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer： An objective performance trial ［J］. J Clin Oncol， 2022 40（）： 8568-8568.
26 WU D， NIE J， HU W H， et al. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer［J］. Int J Cancer， 2020， 147（12）： 3453-3460.
27 WANG F， QIN S K， SUN X C， et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab： data derived from a multicenter phase 2 trial［J］. J Hematol Oncol， 2020， 13（1）： 47.
Options
Outlines

/

〈 〉